Zhong Ji Longevity Science : VOLUNTARY ANNOUNCEMENT COOPERATION AGREEMENT

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Zhong Ji Longevity Science Group Limited

中 基 長 壽 科 學 集 團 有 限 公 司

(formerly known as ASIA PACIFIC SILK ROAD INVESTMENT COMPANY LIMITED亞太絲路投資有限公司)

(Incorporated in Bermuda with limited liability)

(Stock Code: 767)

VOLUNTARY ANNOUNCEMENT

COOPERATION AGREEMENT

This announcement is made by Zhong Ji Longevity Science Group Limited (the ''Company'') on a voluntary basis.

The board (the ''Board'') of directors (the ''Director(s)'') of the Company is pleased to announce that on 11 May 2021, the Company and 青島黃海醫藥經營有限公司 (''Qingdao Huanghai Pharmaceutical'') entered into a cooperation agreement (the ''Cooperation Agreement''), pursuant to which the parties intend to jointly invest in and establish a company with limited liability (the ''Joint Venture''). It is intended that the Joint Venture shall be incorporated in Qingdao and owned by the Company and Huanghai Pharmaceutical as to 51% and 49%, respectively. The Joint Venture will cooperate with the Company and advanced medical institutions in Hong Kong mainly on the provision of cancer prevention and early screening, longevity medical examination, immune cell storage services, the distribution of longevity dietary supplements, and the provision of longevity consultation, management, services and solutions. The cooperation shall become effective on the date of the Cooperation Agreement. The registration of the Joint Venture shall be completed and the investment in, and operation of, the Joint Venture shall commence within 90 days thereafter.

- 1 -

INFORMATION ON QINGDAO HUANGHAI PHARMACEUTICAL

青島黃海製藥有限責任公司 (Qingdao Huanghai Pharmaceutical Co., Ltd.*) (''Huanghai Pharmaceutical'') is one of the largest integrated professional drug manufacturers in Qingdao with an excellent reputation in the industry. Established in 1959, it has a production base with a site area of over 200 mu and more than 600 employees in Qingdao National High-tech Industrial Development Zone. It has over 100 products, including nifedipine sustained-release tablets, isosorbide mononitrate sustained-release tablets, metformin hydrochloride sustained-release tablets, 元順 (Yuanshun*), compound paracetamol and amantadine hydrochloride tablets, and compound glycyrrhiza oral solution, in the forms of tablet, capsule, oral liquid preparation and small-volume injection with a special focus on sustained-release preparations. One of its key products, namely nifedipine sustained-release tablets, was named a Qingdao Top Brand Product and Shandong Top Brand Product with a market share of over 70%. Qingdao Huanghai Pharmaceutical, a wholly-owned subsidiary of Huanghai Pharmaceutical, is responsible for the sales of all products of Huanghai Pharmaceutical. In 2019, Huanghai Pharmaceutical recorded sales of over RMB1.5 billion. Fellow subsidiaries include, among others, Qingdao Huanghai FC, 青島黃海生物製藥有限公司 (Qingdao Huanghai Biological Pharmaceutical Co., Ltd.*) and 青島黃海健康體檢中心 (Qingdao Huanghai Health Examination Center*).

REASONS FOR AND BENEFITS OF THE ESTABLISHMENT OF THE JOINT VENTURE

The Board believes that the establishment of the Joint Venture will help the Group further refine the global layout of its longevity science business, tap into powerful resources, achieve synergies and realise mutual support, thereby bringing stable and sustainable revenue growth to the Group in the long run.

By order of the Board

Zhong Ji Longevity Science Group Limited

Yan Li

Chairman

Hong Kong, 11 May 2021

As at the date of this announcement, the Directors are:

Executive Directors	Independent non-executive Directors
Mr. Yan Li (Chairman)	Mr. Tam Ho Leung Simon
Mr. Wang Hongxin (Chief Executive Officer)	Ms. Wang Weixia
Mr. Yeung Siu Keung	Mr. Chai Nan
Ms. Cao Xie Qiong
Non-executive Director
Ms. Choi Ngai Wah

In the case of any inconsistency, the English text of this announcement shall prevail over the Chinese text.

• For identification purposes only

- 2 -